Ryoncil® commercial launch update and product pipeline

New york, jan. 30, 2025 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the u.s. commercial launch of ryoncil® (remestemcel-l) for steroid-refractory acute graft-versus-host disease (sr-agvhd) in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline.
MESO Ratings Summary
MESO Quant Ranking